Turning to Wall Street, the analysts’ consensus rating for Belite Bio is Strong Buy, based on five Buy and a single Hold ...

The aggregate gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting ...

KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued ...

GRI Bio, Inc. has announced positive topline results from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The trial met its primary and ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

As of Friday, November 28, ImmunityBio, Inc.’s IBRX share price has surged by 11.03%, which has investors questioning if this is right time to sell.

Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far ...

Telesis Bio reaches a new partnership with laboratory automation and innovation company Beckman Coulter Life Sciences. The partnership aims to create efficient and scalable biofoundries and deliver ...

Learn more about whether Baxter International Inc. or PROCEPT BioRobotics Corporation is a better investment based on AAII's ...

Nuvation Bio stock is downgraded as price reflects Ibtrozi’s strong launch. Get insights on NUVB stock's forward revenue and investor strategies.

Investing.com -- KALA BIO, Inc. (NASDAQ:KALA) stock surged 28.3% in premarket trading Monday following the announcement of a $6 million securities purchase agreement with private investor David E.

Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...